Minimal residual disease, metastasis and immunity

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Badia-Ramentol, Jordi
• dc.contributor.author Linares Aceituno, Jenniffer Lissethe
• dc.contributor.author Gómez-Llonín, Andrea
• dc.contributor.author Calon, Alexandre
• dc.date.accessioned 2021-05-25T06:32:07Z
• dc.date.available 2021-05-25T06:32:07Z
• dc.date.issued 2021
• dc.description.abstract Progression from localized to metastatic disease requires cancer cells spreading to distant organs through the bloodstream. Only a small proportion of these circulating tumor cells (CTCs) survives dissemination due to anoikis, shear forces and elimination by the immune system. However, all metastases originate from CTCs capable of surviving and extravasating into distant tissue to re-initiate a tumor. Metastasis initiation is not always immediate as disseminated tumor cells (DTCs) may enter a non-dividing state of cell dormancy. Cancer dormancy is a reversible condition that can be maintained for many years without being clinically detectable. Subsequently, late disease relapses are thought to be due to cancer cells ultimately escaping from dormant state. Cancer dormancy is usually associated with minimal residual disease (MRD), where DTCs persist after intended curative therapy. Thus, MRD is commonly regarded as an indicator of poor prognosis in all cancers. In this review, we examine the current understanding of MRD and immunity during cancer progression to metastasis and discuss clinical perspectives for oncology.
• dc.format.mimetype application/pdf
• dc.identifier.citation Badia-Ramentol J, Linares J, Gómez-Llonin A, Calon A. Minimal residual disease, metastasis and immunity. Biomolecules. 2021 Jan 20; 11(2): 130. DOI: 10.3390/biom11020130
• dc.identifier.doi http://dx.doi.org/10.3390/biom11020130
• dc.identifier.issn 2218-273X
• dc.identifier.uri http://hdl.handle.net/10230/47644
• dc.language.iso eng
• dc.publisher MDPI
• dc.rights Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword CTC
• dc.subject.keyword DTC
• dc.subject.keyword MRD
• dc.subject.keyword Dormancy
• dc.subject.keyword Immunity
• dc.subject.keyword Metastasis
• dc.subject.keyword Therapy
• dc.title Minimal residual disease, metastasis and immunity
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion